Zhejiang Cancer Hospital: clinical-trial pipeline
Zhejiang Cancer Hospital is the sponsor of 281 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 81 are not yet finished and 4 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 134 |
| Not applicable | 93 |
| Phase 3 | 22 |
| Phase 1/2 | 11 |
| Phase 1 | 7 |
| Phase 4 | 7 |
| Early phase 1 | 4 |
| Phase 2/3 | 3 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 156 |
| Recruiting | 53 |
| Completed | 42 |
| Not yet recruiting | 22 |
| Active, not recruiting | 6 |
| Suspended or halted | 2 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 253 |
| Gastroenterology and liver | 33 |
| Women's health and obstetrics | 17 |
| Cardiovascular | 5 |
| Haematology | 3 |
| Nephrology and urology | 3 |
| Neurology | 3 |
| Respiratory | 3 |
| Infectious disease and vaccines | 2 |
| Musculoskeletal | 2 |
| Psychiatry and mental health | 2 |
| Rare and genetic diseases | 1 |
Countries
| Country | Trials |
|---|---|
| China | 246 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-02 | New trial posted | Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Can… |
| 2026-10-02 | New trial posted | Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal I… |
| 2026-09-30 | New trial posted | An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment… |
| 2026-08-31 | New trial posted | Platinum-Free Regimen in Nasopharyngeal Carcinoma |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07554157 | Development of a Pan-Cancer Screening Model Based on Blood Biomarkers | Not applicable | Active, not recruiting | China |
| NCT07271823 | Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer | Not applicable | Active, not recruiting | China |
| NCT07014410 | Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast… | Phase 2 | Recruiting | China |
| NCT07326150 | Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Panc… | Not applicable | Active, not recruiting | China |
| NCT05148767 | UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer | Phase 4 | Recruiting | China |
| NCT06140576 | The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment… | Phase 1/2 | Not yet recruiting | China |
| NCT06195670 | Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Cape… | Phase 1/2 | Not yet recruiting | China |
| NCT07538635 | CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. | Phase 2 | Recruiting | China |
| NCT07177456 | Study on Safety and Efficacy of UCB-MNCs for Radiation-induced Lung Injury | Early phase 1 | Not yet recruiting | |
| NCT05514275 | Radiotherapy Combined With Endostatin and Capecitabine for NPC | Phase 2 | Recruiting | China |
| NCT06086197 | A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL | Phase 2 | Recruiting | China |
| NCT06911086 | SH-LPS System in Preoperative Planning for Liver Resection | Phase 2/3 | Not yet recruiting | |
| NCT06832267 | Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL | Not applicable | Recruiting | China |
| NCT07325630 | Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer | Phase 2 | Recruiting | China |
| NCT07162714 | SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer | Phase 2 | Recruiting | China |
| NCT06741020 | Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma | Phase 1/2 | Recruiting | China |
| NCT07180914 | A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Pre… | Not applicable | Not yet recruiting | |
| NCT07175207 | Study on Safety and Efficacy of UCB-MNCs for Chronic Radiation Enteritis | Early phase 1 | Not yet recruiting | China |
| NCT07855757 | Retlirafusp Alfa Plus SOX and Intraperitoneal Nab-Paclitaxel for Advanced Gastric/GEJ Cancer With Malignant A… | Not applicable | Active, not recruiting | China |
| NCT05920863 | Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage… | Phase 2 | Recruiting | China |
| NCT06538896 | Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer… | Phase 2 | Recruiting | China |
| NCT05813626 | Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | Phase 2 | Active, not recruiting | China |
| NCT05557578 | GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence | Phase 2 | Recruiting | China |
| NCT06609551 | ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A S… | Phase 3 | Recruiting | China |
| NCT06214195 | The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity | Phase 3 | Recruiting | China |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Zhejiang Cancer Hospital clinical trials: 81 open, 25 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/zhejiang-cancer-hospital/, data as of 2026-10-25.